Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 3/20 | 0.54 |
| ▸ | DPP4 | P27487 | 2/20 | 0.53 |
| ▸ | MYC | P01106 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.49 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.48 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.48 |
| ▸ | HMGB1 | P09429 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HNF4A | P41235 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 1/20 | 0.42 |
| ▸ | CA2 | P00918 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2242560 | 0.85 | BCAT2 (0.55) | FOLH1DPP4ALDH1A1GAATSHR | |
| SCHEMBL136079 | 0.84 | FOLH1 (0.59) | FOLH1DPP4ALDH1A1ALOX15HMGB1 | |
| SCHEMBL28324262 | 0.84 | FOLH1 (0.59) | FOLH1DPP4ALDH1A1ALOX15HMGB1 | |
| Benzene SCHEMBL8597142 | 0.84 | FOLH1 (0.59) | FOLH1DPP4ALDH1A1ALOX15HMGB1 | |
| SCHEMBL4240167 | 0.83 | HSD17B10 (0.51) | FOLH1DPP4ALDH1A1HMGB1MAPK1 | |
| SCHEMBL12893382 | 0.83 | DPP4 (0.48) | FOLH1DPP4MYCALDH1A1KMT2A | |
| SCHEMBL1919746 | 0.82 | DPP4 (0.55) | DPP4CYP2C9KDM4EHPGD | |
| SCHEMBL7969105 | 0.82 | FOLH1 (0.56) | FOLH1MYCCYP3A4CYP2C9ALOX12 | |
| SCHEMBL7843765 | 0.82 | FOLH1 (0.56) | FOLH1MYCCYP3A4CYP2C9ALOX12 | |
| Hydrochloric Acid SCHEMBL4542361 | 0.82 | FOLH1 (0.57) | FOLH1DPP4ALDH1A1ALOX15HMGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 82 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019011879-A1 | THERAPEUTIC FOR TREATING CAPILLARY LEAK SYNDROME | HENNING RAINER (CH) | 2019-01-17 | — | — | WO | claimed |
| US-8088890-B2 | Peptides and peptidomimetic compounds, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2012-01-03 | — | — | US | claimed |
| EP-2328925-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-06-08 | — | — | EP | claimed |
| EP-2274328-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | Fibrex Medical Research & Development GmbH (AT) | 2011-01-19 | — | — | EP | claimed |
| WO-2010043444-A2 | PHARMACEUTICAL PREPARATION FOR THE TREATMENT AND/OR PREVENTION OF ISCHEMIA/REPERFUSION INJURY AND THE SEQUELS THEREOF | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-22 | — | — | WO | claimed |
| WO-2010034041-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | WO | claimed |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2010-04-01 | — | — | US | claimed |
| WO-2009137850-A1 | PEPTIDES, PEPTIDOMIMETICS AND DERIVATIVES THEREOF, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | FIBREX MEDICAL RESEARCH & DEVELOPMENT GMBH (AT) | 2009-11-19 | — | — | WO | claimed |
| EP-0683173-B1 | Cyclic adhesion inhibitors | MERCK PATENT GMBH (DE) | 1999-08-11 | — | — | EP | claimed |
| US-5693612-A | USED FOR PROPHYLAXIS AND TREATMENT OF DISORDERS OF THE CIRCULATION, BONES AND IN TUMOR THERAPY, AND AS ANTIMICROBIAL AND ANTIVIRAL ACTIVE COMPOUNDS | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1997-12-02 | — | — | US | claimed |
| JP-7304795-A | — | — | None | — | — | JP | disclosed |
| EP-4153310-B1 | BBETA-15-42 FOR THE TREATMENT OF VIRAL ENDOTHELITIS | F4 PHARMA GMBH (AT) | 2026-02-18 | — | — | EP | disclosed |
| EP-3830284-B1 | BACTERIAL VAGINOSIS DIAGNOSTIC | MOLOGIC LTD (GB) | 2025-02-19 | — | — | EP | disclosed |
| US-20230293640-A1 | COMPOUNDS FOR THE TREATMENT OF ENDOTHELIITIS IN CONTEXT OF VIRALLY CAUSED DISEASES | F4 PHARMA GMBH (AT) | 2023-09-21 | — | — | US | disclosed |
| CN-116348128-A | Bβ15-42 for treating viral endopdermatitis | F4医药有限责任公司 | 2023-06-27 | — | — | CN | disclosed |
| EP-0683173-A1 | Cyclic adhesion inhibitors | MERCK PATENT GmbH (DE) | 1995-11-22 | — | — | EP | disclosed |
| JP-H07304795-A | CYCLOPEPTIDE OF GENERAL FORMULA I | MERCK PATENT GMBH | 1995-11-21 | — | — | JP | disclosed |
| EP-0610439-A1 | PYRIMIDOCYCLOALKANES AS ANGIOTENSIN II ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1994-08-17 | — | — | EP | disclosed |
| US-5234936-A | Treating hypertension, congestive heart failure, hyperlipidemia and hypercholesterolemia | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-08-10 | — | — | US | disclosed |
| WO-1993008171-A1 | PYRIMIDOCYCLOALKANES AS ANGIOTENSIN II ANTAGONISTS | AMERICAN HOME PRODUCTS CORPORATION (US) | 1993-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230293640-A1 | COMPOUNDS FOR THE TREATMENT OF ENDOTHELIITIS IN CONTEXT OF VIRALLY CAUSED DISEASES | FGB, SERPINC1, ECE1 | FOLH1 776/4885DPP4 107/4885MYC 4123/4885 |
| US-20100081787-A1 | PEPTIDES AND PEPTIDOMIMETIC COMPOUNDS, THE MANUFACTURING THEREOF AS WELL AS THEIR USE FOR PREPARING A THERAPEUTICALLY AND/OR PREVENTIVELY ACTIVE PHARMACEUTICAL COMPOSITION | NGLY1, GHRHR, GHSR | FOLH1 3492/4885DPP4 3514/4885MYC 4258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.